Kayne Anderson Rudnick Investment Management LLC Invests $14.46 Million in bluebird bio (BLUE)

Kayne Anderson Rudnick Investment Management LLC bought a new stake in bluebird bio (NASDAQ:BLUE) in the first quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 84,662 shares of the biotechnology company’s stock, valued at approximately $14,456,000. Kayne Anderson Rudnick Investment Management LLC owned 0.17% of bluebird bio as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors have also made changes to their positions in the company. BlackRock Inc. lifted its position in bluebird bio by 1.0% during the first quarter. BlackRock Inc. now owns 3,868,157 shares of the biotechnology company’s stock worth $660,489,000 after purchasing an additional 36,786 shares during the period. Franklin Resources Inc. lifted its position in bluebird bio by 41.3% during the fourth quarter. Franklin Resources Inc. now owns 686,900 shares of the biotechnology company’s stock worth $122,337,000 after purchasing an additional 200,900 shares during the period. Northern Trust Corp lifted its position in bluebird bio by 0.4% during the first quarter. Northern Trust Corp now owns 592,198 shares of the biotechnology company’s stock worth $101,118,000 after purchasing an additional 2,644 shares during the period. Two Sigma Advisers LP lifted its position in bluebird bio by 3,004.0% during the fourth quarter. Two Sigma Advisers LP now owns 462,500 shares of the biotechnology company’s stock worth $82,371,000 after purchasing an additional 447,600 shares during the period. Finally, Geode Capital Management LLC lifted its position in bluebird bio by 9.0% during the fourth quarter. Geode Capital Management LLC now owns 454,997 shares of the biotechnology company’s stock worth $81,034,000 after purchasing an additional 37,588 shares during the period.

In other news, insider Philip D. Gregory sold 2,250 shares of the company’s stock in a transaction that occurred on Thursday, March 1st. The stock was sold at an average price of $200.00, for a total value of $450,000.00. Following the completion of the transaction, the insider now owns 32,522 shares of the company’s stock, valued at $6,504,400. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Also, insider David Davidson sold 22,000 shares of the company’s stock in a transaction that occurred on Monday, April 2nd. The shares were sold at an average price of $167.52, for a total value of $3,685,440.00. The disclosure for this sale can be found here. Insiders sold 46,250 shares of company stock valued at $8,269,990 in the last ninety days. 3.00% of the stock is currently owned by insiders.

bluebird bio stock opened at $187.00 on Friday. bluebird bio has a 1 year low of $74.45 and a 1 year high of $236.17. The company has a market capitalization of $9.49 billion, a PE ratio of -24.25 and a beta of 2.17.

bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Monday, May 7th. The biotechnology company reported ($2.31) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($2.01) by ($0.30). bluebird bio had a negative net margin of 857.55% and a negative return on equity of 27.61%. The firm had revenue of $15.96 million during the quarter, compared to analyst estimates of $5.85 million. During the same period in the prior year, the company earned ($1.68) EPS. The business’s quarterly revenue was up 133.7% compared to the same quarter last year. analysts expect that bluebird bio will post -9.28 EPS for the current fiscal year.

BLUE has been the subject of several recent analyst reports. BidaskClub cut shares of bluebird bio from a “strong-buy” rating to a “buy” rating in a research report on Friday, March 16th. ValuEngine raised shares of bluebird bio from a “buy” rating to a “strong-buy” rating in a research report on Wednesday, May 2nd. Cantor Fitzgerald cut their price objective on shares of bluebird bio from $122.00 to $113.00 and set an “underweight” rating for the company in a research report on Thursday, February 22nd. SunTrust Banks upped their price objective on shares of bluebird bio to $232.00 and gave the stock a “buy” rating in a research report on Thursday, April 19th. Finally, Bank of America boosted their target price on bluebird bio from $185.00 to $218.00 and gave the stock a “neutral” rating in a research note on Thursday, February 22nd. Four investment analysts have rated the stock with a sell rating, nine have issued a hold rating, twelve have assigned a buy rating and one has issued a strong buy rating to the stock. The company presently has a consensus rating of “Hold” and a consensus target price of $195.80.

bluebird bio Company Profile

bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates include Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder; and LentiGlobin, which is in various clinical studies for the treatment of transfusion- transfusion-dependent ß-thalassemia and severe sickle cell disease.

Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio (NASDAQ:BLUE).

Institutional Ownership by Quarter for bluebird bio (NASDAQ:BLUE)

Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply